To quantify the efficacy of pneumococcal vaccination in preventing both pneumococcal infection-related and other clinically-relevant outcomes in adults.
How were the studies combined?
The studies were combined by two methods: Mantel-Haenszel ddds ratios and DerSimonian and Laird summary rate differences.
How were differences between studies investigated?
Separate Q-statistics were calculated to assess heterogeneity for the 9 outcomes where data were provided for 2 or more studies.
Stratified analyses were performed to assess the effect of 5 variables postulated to influence the efficacy of the pneumococcal vaccines: number of vaccine valences employed, location of the study, study quality, mean patient followup time, and risk of pneumococcal infection in the study population.
Results of the review
Nine RCTS are included (40,431 patients). Three reported data on two distinct vaccine and control study groups.
The summary rate differences and 95% confidence intervals (CIs) for the clinical outcomes (expressed as the number of cases per 1000) were: definitive pneumococcal pneumonia, 4 (95% CI: 0, 7, non significant);definitive pneumococcal pneumonia (vaccine types only), 8 (95% CI: 1, 16, p<0.05); presumptive pneumococcal pneumonia, 13 (95% CI: -21, 47, non significant); presumptive pneumococcal pneumonia (vaccine types only), 16 (95% CI: -3, 35, non significant); pneumonia (all causes), 6 (95% CI: -1, 13, non significant); bronchitis, 8(95% CI: 0, 15, non significant); mortality (all causes), 1 (95% CI: -6, 8, non significant); mortality due to pneumonia, 2 (95% CI: -2, 5, non significant); and mortality due to pneumococcal infection, -3 (95% CI: -6,o 0, non significant). Of the stratified analyses, only the comparisons of high-and low-risk populations showed a consistent relationship between these factors and vaccine efficacy. Summary rate differences (expressed as the number per 1000) demonstrated a protective effect in low-risk groups for: definitive pneumococcal pneumonia, 11 (95% CI: 2, 19, p<0.05); presumptive pneumococcal pneumonia, 41 (95% CI: 29, 54, p<0.05); and presumptive pneumococcal pneumonia (vaccine types only), 25 (95% CI: 15, 35, p<0.05). No protective effect was found for any of the study outcomes for high-risk patients.
Side-effects were reported in 3 studies. These were erythema and fever; no life threatening or fatal side-effects were reported in any of these studies.
